Barth Rolf F, Yang Weilian, Huo Tianyao, Riley Kent J, Binns Peter J, Grecula John C, Gupta Nilendu, Rousseau Julia, Elleaume Hélène
Department of Pathology, The Ohio State University, Columbus, OH 43210, USA.
Appl Radiat Isot. 2011 Dec;69(12):1813-6. doi: 10.1016/j.apradiso.2011.03.019. Epub 2011 Mar 21.
In this report we have summarized our studies to optimize the delivery of boronophenylalanine (BPA) and sodium borocaptate (BSH) for boron neutron capture therapy (BNCT) of F98 glioma bearing rats. These results have been compared to a chemoradiotherapeutic approach using the same tumor model. The best survival data from our BNCT studies were obtained using a combination of BPA and sodium borocaptate BSH administered via the internal carotid artery, in combination with blood-brain barrier disruption (BBB-D). This treatment resulted in a mean survival time (MST) of 140 d with a 25% cure rate. The other approach combined intracerebral administration of carboplatin by either convection enhanced delivery (CED) or Alzet pump infusion, followed by external beam photon irradiation. This resulted in MSTs of 83 d and 112 d, respectively, with a cure rate of 40% for the latter. However, a significant problem that must be solved for both BNCT and this new chemoradiotherapeutic approach is how to improve drug uptake and microdistribution within the tumor.
在本报告中，我们总结了我们的研究，以优化硼苯丙氨酸（BPA）和硼卡醇钠（BSH）的给药方式，用于对携带F98胶质瘤的大鼠进行硼中子俘获疗法（BNCT）。这些结果已与使用相同肿瘤模型的放化疗方法进行了比较。我们的BNCT研究中，最佳生存数据是通过经颈内动脉联合血脑屏障破坏（BBB-D）给予BPA和硼卡醇钠（BSH）获得的。这种治疗方法导致平均生存时间（MST）为140天，治愈率为25%。另一种方法是通过对流增强递送（CED）或Alzet泵输注进行脑内卡铂给药，随后进行外照射光子放疗。这分别导致MST为83天和112天，后者的治愈率为40%。然而，对于BNCT和这种新的放化疗方法来说，一个必须解决的重大问题是如何提高肿瘤内的药物摄取和微分布。
